(4-butoxyphenyl)-(4-hydroxyphenyl)-methanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-butoxyphenyl)-(4-hydroxyphenyl)-methanone
• 英文别名: (4-Butoxyphenyl)-(4-hydroxyphenyl)methanone
• 化学式: C₁₇H₁₈O₃
• 分子量: 270.328
• InChiKey: RMETYTQPAHPUCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  丁氧基苯 、 对羟基苯甲酸 在 indium(III) chloride 、 二甲基一氯硅烷 作用下， 以 1,2-二氯乙烷 为溶剂， 以60%的产率得到(4-butoxyphenyl)-(4-hydroxyphenyl)-methanone
  参考文献：
  名称：

  In(III)-Mediated Chemoselective Dehydrogenative Interaction of ClMe₂SiH with Carboxylic Acids:  Direct Chemo- and Regioselective Friedel−Crafts Acylation of Aromatic Ethers

  摘要：

  Chemoselective dehydrogenative interaction of ClMe2SiH with a carboxylic acid group in the presence of InX3 is reported. C-13 NMR investigation revealed the formation of PhCOOSi(Cl)Me-2 as the major transient intermediate. Chemo- and regioselective Friedel-Crafts acylation of aromatic ethers directly from carboxylic acids was established.

  DOI：

  10.1021/ol062723e

文献信息

• [EN] TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ALCÉNIQUES TÉTRASUBSTITUÉS ET LEUR UTILISATION
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2016196342A1

  公开（公告）日：2016-12-08

  Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

  本文披露了化合物或其药用可接受盐，并使用这些化合物治疗乳腺癌的方法，通过向需要治疗的受试者施用这些化合物或其药用可接受盐的治疗有效量。乳腺癌可能是ER阳性乳腺癌，需要治疗的受试者可能表达突变的ER-α蛋白。
• BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE
  申请人：Sadar Marianne D.

  公开号：US20130109758A1

  公开（公告）日：2013-05-02

  This invention provides compounds having a structure of Formula (I). Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
• US9309211B2
  申请人：——

  公开号：US9309211B2

  公开（公告）日：2016-04-12
• In(III)-Mediated Chemoselective Dehydrogenative Interaction of ClMe₂SiH with Carboxylic Acids:  Direct Chemo- and Regioselective Friedel−Crafts Acylation of Aromatic Ethers
  作者：Srinivasarao Arulananda Babu、Makoto Yasuda、Akio Baba

  DOI：10.1021/ol062723e

  日期：2007.2.1

  Chemoselective dehydrogenative interaction of ClMe2SiH with a carboxylic acid group in the presence of InX3 is reported. C-13 NMR investigation revealed the formation of PhCOOSi(Cl)Me-2 as the major transient intermediate. Chemo- and regioselective Friedel-Crafts acylation of aromatic ethers directly from carboxylic acids was established.